Capsida has raised $50.0M in total across 1 funding round.
Capsida's investors include NanoDimension, Westlake Village BioPartners.
# Capsida Biotherapeutics: A Clinical-Stage Gene Therapy Company
Capsida Biotherapeutics is not a technology company in the traditional sense, but rather a clinical-stage genetic medicine company developing targeted, intravenously-delivered gene therapies for rare neurological and genetic disorders.[1][4] The company's core mission is to create a new class of disease-modifying and potentially curative treatments by combining proprietary adeno-associated virus (AAV) engineering with cargo optimization, translational biology, and in-house manufacturing—all integrated under one roof.[1][3]
Capsida serves patients with serious genetic disorders that currently lack effective treatments, focusing initially on three wholly-owned programs: a potential first-in-class therapy for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), a potential best-in-class therapy for Parkinson's disease associated with GBA mutations (PD-GBA), and a potential best-in-class therapy for Friedreich's ataxia (FA).[1][4] The company solves a critical problem in gene therapy: delivering therapeutic genes across the blood-brain barrier non-invasively via intravenous infusion, which avoids invasive procedures and potentially increases treatment effectiveness.[5]
Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners, originating from groundbreaking research conducted in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech.[4] This academic foundation provided the company with deep expertise in AAV biology and CNS gene delivery—critical capabilities that distinguish Capsida from competitors. The company's founding reflected a recognition that existing gene therapy approaches had significant limitations in targeting the central nervous system, and that engineered solutions could unlock new therapeutic possibilities.
Capsida's competitive advantages center on its fully integrated platform and superior capsid engineering:
Capsida operates at the intersection of two major biotech trends: the maturation of gene therapy as a therapeutic modality and the growing recognition that CNS diseases represent a massive unmet medical need. The company's timing is particularly advantageous because:
Capsida's influence extends beyond its own pipeline—by demonstrating that engineered AAV vectors can achieve superior CNS tropism and manufacturability, the company is helping to establish new standards for what gene therapy platforms should achieve.
Capsida stands at an inflection point. The company has transitioned from preclinical validation to clinical development, with CAP-002 in the SYNRGY Phase 1/2a trial for STXBP1-DEE and PD-GBA on track to enter clinical development in Q2 2025.[4] The critical question ahead is whether clinical efficacy will match the promise of preclinical data—a challenge that will determine whether Capsida's platform becomes a standard approach for CNS gene therapy or remains a specialized solution.
Looking forward, the company's trajectory will be shaped by clinical trial outcomes, manufacturing scale-up success, and the ability to expand its pipeline beyond its current three programs. If Capsida can demonstrate durable therapeutic benefit in early-stage trials while maintaining manufacturing quality and cost-effectiveness, it could fundamentally reshape how gene therapies are developed and manufactured across the industry. The convergence of superior science, integrated operations, and strategic partnerships positions Capsida as a potential category-defining company in next-generation genetic medicine.
Capsida has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $50.0M Series A | NanoDimension, Westlake Village BioPartners |
